Download biomedica product list
Biomarkers for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder affecting approximately around 1 in 10 people globally (1).
IBS is characterized by recurrent abdominal pain and changes in bowel habits. The exact causes of IBS is unknown but stress, gastrointestinal infections and a family history of IBS may play a role (1,2). IBS is usually a lifelong problem and symptoms have an effect on daily life. Managing symptoms through diet and lifestyle changes can improve the quality of life (2, 3, 4) .
Accepted biomarkers for IBS are still missing. Recent studies have shown that Leucine-rich alpha glycoprotein (LRG) may be a novel marker to evaluate disease activity and mucosal healing in IBS (5, 6). Moreover, researchers have recently proposed that serum LRG may be a potential diagnostic marker for pediatric IBD (7).
Biomarkers for Irritable Bowel Syndrome
Leucine-rich alpha glycoprotein (LRG)
Leucine-rich alpha-2 glycoprotein (LRG) (also named LRG1) has a molecular weight of 50 kDa glycoprotein and contains repetitive sequences with a leucine-rich motif. LRG derives predominantly from immune cells i.e. neutrophils, macrophags but is also secreted by intestinal epithelial cells and hepatocytes (8) in response to various cytokines (TNF-alpha, IL-6 and IL-22).
LRG has been identified as an inflammatory biomarker for various immune-mediated diseases including IBD, rheumatoid arthritis, juvenile idiopathic arthritis and others (8).
LRG can be measured in human serum and plasma samples by ELISA Assay
LRG ELISA (cat. no. BI-LRG) – developed and manufactured by BIOMEDICA
- RELIABLE – validated following international quality guidelines (FDA, EMA, ICH) . The validation data can be found here.
- REFERENCE values provided for normal and pathological samples
- OPTIMIZED – assay range optimized for clinical samples, no additional testing required
- EASY – results in 3.5 h (protocol booklet)
- CONVENIENT – all reagents included; 7 pre-diluted standards/calibrators, 2 controls and sufficient assay buffer
Example of a Biomedica ELISA Assay Kit
Literature
- Global burden of irritable bowel syndrome: trends, predictions and risk factors. Black CJ et al., Nat Rev Gastroenterol Hepatol. 2020; 17(8):473-486. PMID: 32296140.
- Irritable bowel syndrome. Ford AC et al., Lancet. 2020; 396(10263):1675-1688. PMID: 33049223.
- A Discussion of Whether Various Lifestyle Changes can Alleviate the Symptoms of Irritable Bowel Syndrome. Okawa Y. Healthcare (Basel). 2022; 10(10):2011. PMID: 36292457.
- Irritable bowel syndrome: treatment based on pathophysiology and biomarkers. Camilleri M, Boeckxstaens G. Gut. 2023;72(3):590-599. PMID: 36307180.
- Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Yasutomi E et al., Sci Rep. 2021; 27;11(1):11086.
- Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Shimoyama Tet al., Inflamm Bowel Dis. 2023; 29(9):1399-1408.
- Significance of Serum Leucine-rich Alpha-2 Glycoprotein as a Diagnostic Marker in Pediatric Inflammatory Bowel Disease. Yoshimura S et al., Kobe J Med Sci. 2024; 69(4):E122-E128. PMID: 38379274.
- Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease. Yoshimura Tet a., 2021; 2021:8825374. PMID: 33623482.